-
Hard Copy
-
CD ROM
-
Electronic (PDF)
-
Enterprisewide
US Oncologist Survey 2012: Optimizing Treatment for Advanced Prostate Cancer
The Assessment Group, November 2011, Pages: 50
Patient case scenarios that progressively unfold, presented to 200 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients. This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US oncologists on the treatment of patients with advanced melanoma.
This report allows you to:
- Understand what occurs with actual patients
- Access the most up-to-date prescribing trends
- Gain actionable data for developing and improving your market strategies
- Pinpoint needs of your target audience
- Focus resources to maximize the effectiveness of your budget
- Understand where your product fits
- Understand where your competitor’s product fits
- Design messages to advance brand performance
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Advanced Melanoma
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Medical specialty
Attended medical school in the US
Gender of survey respondents
Geographic settings
Practice settings
Minimal acceptable level of evidence in determining treatment regimen
Chapter 3: Treatment of Stage III Melanoma with Micrometastatic Axillary Nodes
Confidence in treating this patient to an optimal outcome
Next step in management
Laboratory studies to order
First-line chemotherapy regimen
Factors influencing treatment decision
Second-line treatment regimen
Factors influencing treatment decision
Chapter 4: Treatment of Elderly Woman with Metastatic Disease at the Time of Diagnosis
Confidence in treating this patient to an optimal outcome
Laboratory studies to order
BRAF Mutation Description
First-line chemotherapy regimen
Expected response rate with vemurafenib (PLX4032)
Anticipated complications expected following treatment with vemurafenib (PLX4032)
Chapter 5: Young Man with Recurrent Melanoma Metastatic to Liver and Bone
Confidence in treating this patient to an optimal outcome
Laboratory studies to order
First-line chemotherapy regimen
Mechanism of action of Yervoy (ipilimumab)
Managing side effect of treatment
Next step in management
Chapter 6: Patient with solitary metastatic lesion
Confidence in treating patient to an optimal outcome
First-line chemotherapy regimen
Factors influencing treatment decisions
Next step in management
Barriers to an optimal outcome
Chapter 7: Summary
Appendix A: Survey Instrument
- Schering
- Merck
- Genentech
- Ben Venue Laboratories
- GlaxoSmithKline
- Novartis
- Bristol-Myers Squibb
- Ind-Swift Laboratories
- Organon Pharma
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
